Valuation: Aura Biosciences, Inc.

Market Cap 744M 676M 624M 563M 1.06B 69.53B 1.1B 7.52B 2.97B 37.52B 2.79B 2.73B 119B P/E 2026 *
-4.76x
P/E 2027 * -5.66x
Enterprise Value 744M 676M 624M 563M 1.06B 69.53B 1.1B 7.52B 2.97B 37.52B 2.79B 2.73B 119B EV / Sales 2026 *
-
EV / Sales 2027 * 151x
Free-Float
91.4%
Yield 2026 *
-
Yield 2027 * -
1 day-0.97%
1 week-6.54%
Current month+16.45%
1 month+17.21%
3 months-6.90%
6 months-7.62%
Current year+31.19%
1 week 6.86
Extreme 6.865
7.53
1 month 5.88
Extreme 5.88
7.94
Current year 4.73
Extreme 4.73
9.54
1 year 4.73
Extreme 4.73
9.54
3 years 4.34
Extreme 4.345
12.38
5 years 4.34
Extreme 4.345
24.83
10 years 4.34
Extreme 4.345
26.16
Manager TitleAgeSince
Chief Executive Officer 53 2026-04-29
Director of Finance/CFO 53 2026-09-01
Chief Operating Officer 52 2026-08-09
Director TitleAgeSince
Director/Board Member 41 2019-03-31
Chairman 61 2020-12-31
Director/Board Member 55 2021-04-30
Date Insider Type Main position Quantity % Market Cap. Importance
9/1/26 Free

Chief Financial Officer

70,000 0.0675%
9/1/26 Free

Chief Operating Officer

400,000 0.3857%
9/1/26 Free

Chief Technology Officer

175,000 0.1687%
Change 5-day change 1-year change 3-year change Capi.($)
-0.97%-6.54%+30.00%-11.73% 744M
+1.15%-2.81%+55.79%+71.12% 66.37B
+1.80%-0.64%+10.30%+92.99% 58.86B
+1.00%+0.99%+26.64%+87.63% 55.22B
+0.48%-2.53%+9.73%+121.14% 47.21B
-2.69%-6.38%+19.19%+25.79% 42.45B
-0.70%+4.93%+17.77%+45.03% 36.44B
-2.50%-15.73%+135.31%+662.73% 35.19B
+0.69%-1.21%+83.61%+58.47% 32.66B
-0.83%+1.98%-38.27%+390.98% 26.73B
Average -0.26%-2.63%+35.01%+154.41% 40B
Weighted average by Cap. +0.08%-2.19%+35.32%+147.21%

Financials

2026 *2027 *
Net sales - 4.92M 4.47M 4.13M 3.73M 7.03M 460M 7.3M 49.77M 19.68M 248M 18.48M 18.09M 785M
Net income -147M -133M -123M -111M -209M -13.7B -217M -1.48B -586M -7.39B -550M -539M -23.36B -158M -143M -132M -119M -225M -14.73B -234M -1.59B -630M -7.95B -591M -579M -25.11B
Net Debt - -
Projected Income Statement - Annual - Aura Biosciences, Inc.
Logo Aura Biosciences, Inc.
Aura Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors that aim to preserve organ function. The Company’s lead candidate, bel-sar (AU-011), is in late-stage development for primary choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer. It is developing bel-sar as a potential first-line vision-sparing treatment option for early intervention in small choroidal melanoma and/or indeterminate lesions, avoiding the need for radiotherapy and reducing the risk for metastasis for these patients. Bel-sar is a virus-like drug conjugate (VDC) consisting of a human papillomavirus (HPV)-derived virus-like particle (VLP) and a phthalocyanine dye, a light-activated cytotoxic payload. The Company’s platform is designed to enable the targeting of a range of solid tumors using VLP, that can be conjugated with drugs or loaded with nucleic acids to create VDCs.
Employees
113
Date Price Change Volume
26-11-17 US$7.150 -0.97% 627,641
26-11-16 US$7.220 +1.55% 779,117
26-11-13 US$7.110 0.00% 610,303
26-11-12 US$7.110 -6.57% 1,006,708
26-11-11 US$7.610 -0.52% 648,547
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Aura Biosciences, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
7.150USD
Average target price
16.60USD
Spread / Average Target
+132.17%
  1. Stock Market
  2. Stocks
  3. AURA Stock